Targeted Treatment for RET Fusion-Positive Advanced Non-Small Cell Lung Cancer (A LUNG-MAP Treatment Trial)
Status:
Recruiting
Trial end date:
2023-02-28
Target enrollment:
Participant gender:
Summary
This phase II LUNG-MAP treatment trial studies how well selpercatinib works in treating
patients with RET fusion-positive non-small cell lung cancer that is stage IV or has come
back (recurrent). Selpercatinib may stop the growth of tumor cells by blocking some of the
enzymes needed for cell growth.